As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific antibodies (BsAbs) have been US Food and Drug Administration (FDA) approved for the ...
Receptors on B and T cells hint at what the immune system is targeting. An AI approach called Mal-ID developed increases diagnostic accuracy, particularly for autoimmune diseases. Your immune system ...
MDX2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells, enhancing antitumor activity and reducing antigen loss. The therapy's design limits cytokine release syndrome, showing improved ...
As of September 26, 2024, 33 CD19 CAR T-naïve patients with LBCL (median age, 66 years; median number of previous therapies, 3) received allogeneic CAR T cells. CAR T-cell expansion was observed ...
Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's positive outcomes. The FELIX trial reported a 63% complete remission rate, with 42 ...
Epstein-Barr virus (EBV) infected and reprogrammed autoreactive B cells in patients with systemic lupus erythematosus (SLE) to become activated antigen-presenting cells. EBV-infected B cells in ...
A new artificial intelligence (AI) tool can simultaneously assess blood samples for infections, autoimmune diseases, and vaccine responses, according to a new study. The algorithm analyzed genes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results